Gotham Asset Management LLC Sells 74,321 Shares of Myriad Genetics (MYGN)

Gotham Asset Management LLC lowered its position in shares of Myriad Genetics (NASDAQ:MYGN) by 33.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 144,771 shares of the company’s stock after selling 74,321 shares during the period. Gotham Asset Management LLC owned 0.21% of Myriad Genetics worth $4,972,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently made changes to their positions in MYGN. BB&T Securities LLC increased its stake in Myriad Genetics by 347.7% during the 4th quarter. BB&T Securities LLC now owns 5,990 shares of the company’s stock worth $205,000 after acquiring an additional 4,652 shares during the period. Macquarie Group Ltd. increased its stake in Myriad Genetics by 7.8% during the 4th quarter. Macquarie Group Ltd. now owns 145,500 shares of the company’s stock worth $4,998,000 after acquiring an additional 10,500 shares during the period. Vident Investment Advisory LLC increased its stake in Myriad Genetics by 6.5% during the 4th quarter. Vident Investment Advisory LLC now owns 115,121 shares of the company’s stock worth $3,954,000 after acquiring an additional 7,029 shares during the period. LPL Financial LLC bought a new position in Myriad Genetics during the 4th quarter worth $226,000. Finally, Meadow Creek Investment Management LLC increased its stake in Myriad Genetics by 19.4% during the 4th quarter. Meadow Creek Investment Management LLC now owns 11,322 shares of the company’s stock worth $389,000 after acquiring an additional 1,836 shares during the period.

How to Become a New Pot Stock Millionaire

Shares of Myriad Genetics (NASDAQ:MYGN) opened at $28.83 on Monday. The firm has a market capitalization of $2,013.78, a price-to-earnings ratio of 15.58, a price-to-earnings-growth ratio of 2.03 and a beta of 0.44. Myriad Genetics has a twelve month low of $17.50 and a twelve month high of $41.57. The company has a quick ratio of 1.81, a current ratio of 2.05 and a debt-to-equity ratio of 0.05.

Myriad Genetics (NASDAQ:MYGN) last issued its earnings results on Tuesday, February 6th. The company reported $0.31 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.24 by $0.07. The firm had revenue of $194.00 million for the quarter, compared to the consensus estimate of $188.72 million. Myriad Genetics had a return on equity of 9.59% and a net margin of 16.67%. The company’s revenue was down 1.3% compared to the same quarter last year. During the same quarter last year, the business posted $0.26 EPS. equities research analysts expect that Myriad Genetics will post 1.15 earnings per share for the current year.

In other Myriad Genetics news, VP Richard M. Marsh sold 37,654 shares of the firm’s stock in a transaction on Monday, January 22nd. The stock was sold at an average price of $40.25, for a total value of $1,515,573.50. Following the sale, the vice president now owns 157,648 shares of the company’s stock, valued at approximately $6,345,332. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Richard M. Marsh sold 13,759 shares of the firm’s stock in a transaction on Friday, January 12th. The shares were sold at an average price of $36.25, for a total value of $498,763.75. Following the completion of the sale, the vice president now directly owns 136,385 shares in the company, valued at approximately $4,943,956.25. The disclosure for this sale can be found here. In the last ninety days, insiders sold 54,533 shares of company stock worth $2,133,272. Company insiders own 6.70% of the company’s stock.

A number of research firms have commented on MYGN. Morgan Stanley upgraded Myriad Genetics from an “underweight” rating to an “equal weight” rating and set a $28.00 price objective on the stock in a research note on Wednesday, March 21st. ValuEngine lowered Myriad Genetics from a “buy” rating to a “hold” rating in a research note on Tuesday, March 13th. BidaskClub lowered Myriad Genetics from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, February 28th. BTIG Research set a $44.00 price objective on Myriad Genetics and gave the stock a “buy” rating in a research note on Wednesday, February 7th. Finally, Leerink Swann raised their price objective on Myriad Genetics from $33.00 to $35.00 and gave the stock a “market perform” rating in a research note on Wednesday, February 7th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and three have issued a buy rating to the company. Myriad Genetics currently has a consensus rating of “Hold” and a consensus target price of $31.42.

COPYRIGHT VIOLATION NOTICE: “Gotham Asset Management LLC Sells 74,321 Shares of Myriad Genetics (MYGN)” was first posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this story on another publication, it was stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.tickerreport.com/banking-finance/3301537/gotham-asset-management-llc-sells-74321-shares-of-myriad-genetics-mygn.html.

Myriad Genetics Profile

Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BART, a DNA sequencing test for hereditary breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.

Institutional Ownership by Quarter for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Netflix  Given Outperform Rating at CIBC
Netflix Given Outperform Rating at CIBC
LVMH Moet Hennessy Louis Vuitton SE  Receives Consensus Rating of “Hold” from Brokerages
LVMH Moet Hennessy Louis Vuitton SE Receives Consensus Rating of “Hold” from Brokerages
Analysts Set Brighthouse Financial  Price Target at $65.54
Analysts Set Brighthouse Financial Price Target at $65.54
Analysts Set ATN International Inc  PT at $63.50
Analysts Set ATN International Inc PT at $63.50
Contrasting IBM  and Arista Networks
Contrasting IBM and Arista Networks
Head to Head Contrast: HD Supply  & W. W. Grainger
Head to Head Contrast: HD Supply & W. W. Grainger


© 2006-2018 Ticker Report. Google+.